Wes Hodkiewicz takes a look at the new-look receiver room in this edition of Packers Daily. Mike Spofford has updates from OTAs and takes a closer look at the wide receivers in this edition of ...

LOS ANGELES — It's 10 a.m. on a Friday at SURFCORE Fitness, a boutique gym in Mid-City, and a 52-year-old woman is following an exercise circuit as her trainer watches on. The fashion consultant ...

Are cookies and chips the new cigarettes? And soda, breakfast cereals and ice cream the new opioids? In his new book, “Diet, Drugs, and Dopamine: The New Science of Achieving a Healthy Weight ...

A doctor has named a type of food we should all eat with every single meal that could have the same effects as Ozempic. The expert explained that this food could “significantly increase ...

An FDA deadline instructing compounding pharmacies and telehealth companies to stop selling compounded versions of Ozempic and Zepbound has not stopped the copycat market, The Wall Street Journal ...

“Let’s address the elephant in the comments section. I am not on Ozempic. I am not sick. I didn’t get a face transplant and I didn’t get a brow lift,” Burke, 41, said in a video shared ...

“I am not on Ozempic. I am not sick. I didn’t get a face transplant, and I didn’t get a brow lift.” She expressed her frustration with the level of projection happening online, calling it ...

Semaglutide, sold under brand names like Ozempic, Rybelsus, and Wegovy, belongs to a class of medications called GLP-1 receptor agonists. While FDA-approved for managing diabetes and aiding weight ...

Ozempic and Wegovy maker Novo Nordisk ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the company is losing its first-mover advantage in the highly competitive obesity drug market.

Shares had skyrocketed after the introduction of Wegovy and diabetes medicine Ozempic, which are both based on the same basic ingredient, semaglutide. At the peak, the company’s market ...

(Reuters) -Ozempic-maker Novo Nordisk on Friday ousted ... Novo launched the NovoPen - the first insulin pen device in 1985. Lars Rebien Sorensen becomes CEO after serving as the head of Novo's ...

Ozempic maker Novo Nordisk NOVO.B-0.94%decrease; red down pointing triangle pushed out its chief executive after losing ground in the anti-obesity drug market, which has caused a steep stock-price ...